Achieve Life Sciences, Inc. (ACHV) Key Metrics
ACHV valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $657.8M
- Enterprise value
- $663.2M
- P/E (TTM)
- —
- Forward P/E
- 35.3
- PEG ratio
- 17.68
- Price / sales
- 5.1
- Price / book
- 64.0
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 2.31
ACHV key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsACHV valuation Price multiples at each fiscal year-end price.
Price / book+86.4%
10.1
2025 · hover or tap a bar for each year
20162025
Free cash flow yield+3.5 pts
−22.8%
2025 · hover or tap a bar for each year
20162025
ACHV returns How much profit the business earns on the capital it uses.
Return on equity+151.8 pts
−257.7%
2025 · hover or tap a bar for each year
20162025
Return on assets+1.4 pts
−135.9%
2025 · hover or tap a bar for each year
20162025
Asset turnover
0.00
2025 · hover or tap a bar for each year
20162025
ACHV per-share figures Results divided by the shares outstanding at year-end.
Revenue per share
$0.00
2025 · hover or tap a bar for each year
20162025
Earnings per share
−$1.25
2025 · hover or tap a bar for each year
20162025
Free cash flow per share
−$1.13
2025 · hover or tap a bar for each year
20162025
Book value per share−24.3%
$0.49
2025 · hover or tap a bar for each year
20162025
Shares outstanding+35.9%
43.6M
2025 · hover or tap a bar for each year
20162025
ACHV financial health Debt, liquidity and how easily interest is covered.
Debt / equity+45.9%
0.69
2025 · hover or tap a bar for each year
20162025
Net debt+$2.9M
−$21.4M
2025 · hover or tap a bar for each year
20162025
Current ratio−19.5%
4.39
2025 · hover or tap a bar for each year
20162025
Interest coverage
-67.0
2025 · hover or tap a bar for each year
20162025
Debt / assets+38.8%
0.36
2025 · hover or tap a bar for each year
20162025
ACHV efficiency & capital use Working capital cycle and where the cash goes.
Days payables outstanding+208 days
2,255 days
2025 · hover or tap a bar for each year
20162025
ACHV valuation history
Fiscal year-endToday10-year median
ACHV returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ACHV debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ACHV cash returned to shareholders
DividendsBuybacksFree cash flow
ACHV price vs earnings per share
Share price at year-endEPS (right axis)
ACHV key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $216.7M | $112.9M | — | — | — | — | — | — | — | — |
| Enterprise value | $195.2M | $88.5M | — | — | — | — | — | — | — | — |
| Price / book | 10.1 | 5.4 | — | — | — | — | — | — | — | — |
| Earnings yield | −25.2% | −35.3% | — | — | — | — | — | — | — | — |
| Free cash flow yield | −22.8% | −26.4% | — | — | — | — | — | — | — | — |
| Shareholder yield (dividends + buybacks) | 0.0% | 0.0% | — | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $4.97 | $3.52 | $4.12 | $2.45 | $7.78 | $8.10 | $10.60 | $24.20 | $268.66 | $1,099.78 |
| Per share | ||||||||||
| Revenue per share | $0.00 | $0.00 | — | — | — | — | — | — | — | — |
| Earnings per share | −$1.25 | −$1.24 | — | — | — | — | — | — | — | — |
| Operating cash flow per share | −$1.13 | −$0.93 | — | — | — | — | — | — | — | — |
| Free cash flow per share | −$1.13 | −$0.93 | — | — | — | — | — | — | — | — |
| Cash per share | $0.84 | $1.07 | — | — | — | — | — | — | — | — |
| Book value per share | $0.49 | $0.65 | — | — | — | — | — | — | — | — |
| Tangible book value per share | $0.45 | $0.59 | — | — | — | — | — | — | — | — |
| Capex per share | $0.00 | $0.00 | — | — | — | — | — | — | — | — |
| Debt per share | $0.34 | $0.31 | — | — | — | — | — | — | — | — |
| Shares outstanding | 43.6M | 32.1M | — | — | — | — | — | — | — | — |
| Change in shares outstanding | +35.9% | — | — | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −257.7% | −409.5% | — | −230.4% | −100.7% | −53.0% | −95.4% | −107.1% | −78.8% | −71.4% |
| Return on invested capital (ROIC) | — | — | — | — | — | −695.7% | −891.0% | −532.1% | — | — |
| Return on assets (ROA) | −135.9% | −137.3% | −120.9% | −108.1% | −74.9% | −47.8% | −80.4% | −87.6% | −56.7% | −47.0% |
| Return on tangible assets | −136.6% | −108.7% | −173.9% | −152.2% | −73.4% | −39.2% | −89.9% | −80.6% | −167.3% | −73.3% |
| Free cash flow margin | — | — | — | — | — | — | — | — | — | −587.3% |
| Financial health | ||||||||||
| Total debt | $15.0M | $10.0M | $16.7M | $16.2M | $15.0M | $169,000 | $362,000 | $35,000 | $27,000 | $106,000 |
| Cash & short-term investments | $36.4M | $34.3M | $15.5M | $24.7M | $43.0M | $35.9M | $16.7M | $14.7M | $5.3M | $25.7M |
| Net debt | −$21.4M | −$24.4M | $1.2M | −$8.5M | −$28.0M | −$35.7M | −$16.3M | −$14.6M | −$5.3M | −$25.6M |
| Debt / equity | 0.69 | 0.48 | — | 1.95 | 0.53 | 0.00 | 0.02 | 0.00 | 0.00 | 0.01 |
| Debt / assets | 0.36 | 0.26 | 0.86 | 0.54 | 0.32 | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 |
| Current ratio | 4.39 | 5.46 | 0.82 | 1.27 | 9.80 | 12.60 | 6.04 | 4.75 | 2.93 | 3.22 |
| Quick ratio | 4.39 | 5.46 | 0.82 | 1.38 | 9.80 | 12.60 | 6.04 | 4.77 | 2.82 | 3.22 |
| Interest coverage | -67.0 | -17.9 | -9.6 | -22.8 | — | -213.8 | — | — | — | — |
| Working capital | $30.8M | $29.8M | −$3.8M | $5.7M | $40.0M | $34.0M | $14.5M | $12.3M | $3.9M | $18.7M |
| Invested capital | $69,000 | −$3.5M | −$263,000 | −$220,000 | $13,000 | $1.6M | $1.7M | $1.2M | $2.6M | −$6.7M |
| Tangible asset value | $19.7M | $18.9M | −$3.7M | $5.9M | $25.4M | $34.4M | $14.9M | $12.5M | $4.3M | $19.0M |
| Net current asset value | $19.6M | $18.7M | −$3.8M | $5.7M | $25.1M | $34.0M | $14.3M | $12.3M | $3.9M | $18.7M |
| Graham net-net per share | $0.37 | $0.52 | — | — | — | — | — | — | — | — |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | — | — | — | $0 | $0 |
| Share buybacks (net) | $0 | $0 | $30,000 | $47 | — | $0 | $0 | $0 | $5 | $0 |
| Capex / revenue | — | — | — | — | — | — | — | — | — | 0.9% |
| Capex / depreciation | 0.01 | 0.00 | 0.09 | 0.00 | 0.07 | 0.07 | 0.21 | 0.16 | 0.16 | 0.24 |
| Stock-based compensation / revenue | — | — | — | — | — | — | — | — | — | 32.6% |
| R&D / revenue | — | — | — | — | — | — | — | — | — | 292.1% |
| SG&A / revenue | — | — | — | — | — | — | — | — | — | 176.5% |
| Efficiency | ||||||||||
| Days sales outstanding | — | — | — | — | — | — | — | — | — | 22.9 |
| Days of inventory on hand | — | — | — | -3,855.7 | — | — | -41.7 | 111.3 | 143.7 | — |
| Days payables outstanding | 2,254.8 | 2,046.6 | 1,823.4 | 1,934.0 | 856.3 | 852.4 | 720.7 | 231.0 | 1,510.5 | — |
| Receivables turnover | — | — | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 15.94 |
| Payables turnover | 0.16 | 0.18 | 0.20 | 0.19 | 0.43 | 0.43 | 0.51 | 1.58 | 0.24 | 0.00 |
| Inventory turnover | — | — | — | — | — | — | — | — | 2.54 | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.12 |
| Average receivables | — | — | $108,000 | $129,000 | $153,000 | — | $7,500 | $8,000 | $259,500 | $317,500 |
| Average payables | $1.4M | $1.3M | $1.1M | $1.3M | $586,500 | $595,500 | $501,500 | $178,500 | $1.2M | $1.7M |
| Average inventory | — | — | — | −$2.5M | — | — | −$29,000 | $86,000 | $111,000 | $0 |
| Intangibles / total assets | 4.3% | 5.2% | 11.5% | 8.2% | 5.6% | 7.2% | 14.8% | 17.5% | 36.0% | 0.0% |
Computed from ACHV's annual financial statements (latest annual report filed March 24, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
ACHV valuation and financial ratios
Achieve Life Sciences earned a return on equity of −257.7% in fiscal 2025. It ended the year with $15.0 million of debt and $36.4 million in cash and short-term investments, a net cash position of $21.4 million.
See the ACHV income statement, the ACHV chart for price history, or the ACHV stock overview for the latest quote and news.
ACHV key metrics FAQ
What is Achieve Life Sciences's return on equity?
Achieve Life Sciences's return on equity (ROE) was −257.7% in fiscal 2025: net income of -$54.6 million on average shareholders' equity of $21.2 million.
How much debt does Achieve Life Sciences have?
Achieve Life Sciences had total debt of $15.0 million at the end of fiscal 2025, a debt-to-equity ratio of 0.69 and more cash than debt.
What is Achieve Life Sciences's free cash flow yield?
Achieve Life Sciences generated -$49.5 million of free cash flow in fiscal 2025, a free cash flow yield of −22.8% on its market value at year-end ($216.7 million).
What is Achieve Life Sciences's current ratio?
Achieve Life Sciences's current ratio was 4.39 at the end of fiscal 2025: current assets were 4.39 times current liabilities.